Disclaimer: All information on this section is of a general nature.
Before making any investment decision, you should consult your adviser.
BARD1 Life Sciences (ASX: BD1) - Lung Cancer Test setback delays path to clinica
On 15 May 2017, BD1 announced the results of a 638-sample lung cancer study using its BARD1 Lung Cancer Test. The study demonstrated that the Test had an overall ROC-AUC score for accuracy in identifying lung cancer of 0.82 in the training sets and 0.725 in the test sets.